Cost-effectiveness of subcutaneous ketamine in the management of chronic cancer pain

Nicola McCaffrey; Thomas Flint; Billingsley Kaambwa; Belinda Fazekas; David Currow; Janet Hardy; Meera Agar; Simon Eckermann

Cost-effectiveness of subcutaneous ketamine in the management of chronic cancer pain

Nicola McCaffrey
, Thomas Flint
, Billingsley Kaambwa
, Belinda Fazekas
, David Currow
, Janet Hardy
, Meera Agar
, Simon Eckermann

Research output: Contribution to conference › Paper › peer-review

Abstract

Study implications:
–No statistically significant difference in responder rates but higher toxicity and worse QOL
–Higher ketamine costs despite lower costs for other medications
–When costs and QOL are jointly considered, ketamine is neither effective nor cost-effective

Original language	English
Number of pages	23
Publication status	Published - May 2015
Event	13th Australian Palliative Care Conference Melbourne: Fit for the future - Melbourne Convention and Exhibition Centre, Melbourne, Australia Duration: 1 Sept 2015 → 4 Sept 2015 Conference number: 13

Conference

Conference	13th Australian Palliative Care Conference Melbourne
Country/Territory	Australia
City	Melbourne
Period	1/09/15 → 4/09/15

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

End-of-life care
palliative medicine
ketamine
pain management

Access to Document

https://www.eiseverywhere.com/ehome/13apcc2015/326858/

Cite this

@conference{b385d8fae14a4ecd9013149450f705b4,

title = "Cost-effectiveness of subcutaneous ketamine in the management of chronic cancer pain",

abstract = "Study implications: –No statistically significant difference in responder rates but higher toxicity and worse QOL –Higher ketamine costs despite lower costs for other medications –When costs and QOL are jointly considered, ketamine is neither effective nor cost-effective",

keywords = "End-of-life care, palliative medicine, ketamine, pain management",

author = "Nicola McCaffrey and Thomas Flint and Billingsley Kaambwa and Belinda Fazekas and David Currow and Janet Hardy and Meera Agar and Simon Eckermann",

year = "2015",

month = may,

language = "English",

note = "13th Australian Palliative Care Conference Melbourne : Fit for the future ; Conference date: 01-09-2015 Through 04-09-2015",

}

TY - CONF

T1 - Cost-effectiveness of subcutaneous ketamine in the management of chronic cancer pain

AU - McCaffrey, Nicola

AU - Flint, Thomas

AU - Kaambwa, Billingsley

AU - Fazekas, Belinda

AU - Currow, David

AU - Hardy, Janet

AU - Agar, Meera

AU - Eckermann, Simon

N1 - Conference code: 13

PY - 2015/5

Y1 - 2015/5

N2 - Study implications: –No statistically significant difference in responder rates but higher toxicity and worse QOL –Higher ketamine costs despite lower costs for other medications –When costs and QOL are jointly considered, ketamine is neither effective nor cost-effective

AB - Study implications: –No statistically significant difference in responder rates but higher toxicity and worse QOL –Higher ketamine costs despite lower costs for other medications –When costs and QOL are jointly considered, ketamine is neither effective nor cost-effective

KW - End-of-life care

KW - palliative medicine

KW - ketamine

KW - pain management

M3 - Paper

T2 - 13th Australian Palliative Care Conference Melbourne

Y2 - 1 September 2015 through 4 September 2015

ER -

Cost-effectiveness of subcutaneous ketamine in the management of chronic cancer pain

Abstract

Conference

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this